Body
Lonza Group AG recently bought Cambrex Corp.’s bioproducts and biopharma businesses.
“This is the largest acquisition in our long company history and represents a significant commitment and leap forward toward achieving our long-time goal of becoming one of the world’s leading suppliers to our existing and new customers in the pharmaceutical, health care and other life sciences industries,” says Stefan Borgas, Lonza CEO. “We are now closer to this goal than ever before.”
…
Want to continue?
Log in or create a FREE account.
By logging in you agree to receive communication from Quality Digest.
Privacy Policy.
Add new comment